NAPSR News: Teva acquires Auspex Pharmaceuticals

WASHINGTON - May 6, 2015 - PRLog -- Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. As a result of this transaction, Auspex will become a wholly owned subsidiary of Teva.

Teva will now have access to Auspex’s innovative biopharmaceutical portfolio which includes the company’s lead compound SD-809 (deutetrabenazine) for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. The compound has been granted orphan drug status by the FDA and a New Drug Application (NDA) will be submitted later this year. Topline data were achieved from a Phase II study of SD-809 in Huntington’s; the results were presented at the American Academy of Neurology’s Annual Meeting in April.

“We believe that combining the Auspex portfolio with our strong research and commercialization capabilities will unlock significant value for Teva’s shareholders,” said Erez Vigodman, President and CEO of Teva. “We are proud and excited to continue to work to bring innovative treatments to the underserved movement disorder markets.”

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!

This acquisition will certainly be beneficial to Teva as they plan to expand their core central nervous system (CNS) franchise. This will without a doubt bolster the need for both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they prefer individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.